

Auxiliary Request 25

Claims:

1. (R)-5-[3-Chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one (Compound 1) for use in the treatment of multiple sclerosis; wherein during initiation of treatment, or upon re-initiation of treatment after drug discontinuation, Compound 1 is to be administered to a human subject orally once daily as follows: 2 mg of Compound 1 on days 1 and 2; 3 mg of Compound 1 on days 3 and 4; 4 mg of Compound 1 on days 5 and 6; 5 mg of Compound 1 on day 7; 6 mg of Compound 1 on day 8; 7 mg of Compound 1 on day 9; 8 mg of Compound 1 on day 10; and 9 mg of Compound 1 on day 11; followed by 10 mg of Compound 1 to be administered orally once daily on days 12, 13, and 14, followed by the maintenance dose of 20 mg of Compound 1 to be administered orally once daily from day 15 onwards.
2. Compound 1 for use according to claim 1, wherein the multiple sclerosis to be treated is relapsing multiple sclerosis.
3. Compound 1 for use according to claim 1, wherein the multiple sclerosis to be treated is relapsing-remitting multiple sclerosis.